Virbac to acquire Sasaeah from ORIX for €280m.

Virbac, a pharmaceutical company, agreed to acquire Sasaeah, a veterinary products manufacturer, from ORIX, a Japanese diversified financial services group, for €280m. “Japan is a key market in the global animal health industry. This acquisition aligns seamlessly with our company's vision for 2030, emphasizing geographic expansion in major markets, the growth of our vaccines segment and the reinforcement of our key species. We are deeply honored to welcome the talented Sasaeah team to our global Virbac family. Together, we look forward to shaping the future of animal health in Japan,” Sébastien Huron, Virbac CEO.